JP2008546792A - Ｐｓｍａ抗体薬物複合体 - Google Patents

Ｐｓｍａ抗体薬物複合体 Download PDF

Info

Publication number
JP2008546792A
JP2008546792A JP2008518359A JP2008518359A JP2008546792A JP 2008546792 A JP2008546792 A JP 2008546792A JP 2008518359 A JP2008518359 A JP 2008518359A JP 2008518359 A JP2008518359 A JP 2008518359A JP 2008546792 A JP2008546792 A JP 2008546792A
Authority
JP
Japan
Prior art keywords
antibody
psma
drug conjugate
antibody drug
abgenix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008518359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008546792A5 (enExample
Inventor
エムエー，ダンシェ
マドン，ポール，ジェイ．
オルソン．ウィリアム，シー．
ドロニナ，スヴェトラーナ，オー．
トキ，ブライアン，イー．
センター，ピーター，ディー．
Original Assignee
ピーエスエムエー ディベロップメント カンパニー，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーエスエムエー ディベロップメント カンパニー，エルエルシー filed Critical ピーエスエムエー ディベロップメント カンパニー，エルエルシー
Publication of JP2008546792A publication Critical patent/JP2008546792A/ja
Publication of JP2008546792A5 publication Critical patent/JP2008546792A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008518359A 2005-06-20 2006-06-20 Ｐｓｍａ抗体薬物複合体 Withdrawn JP2008546792A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69239905P 2005-06-20 2005-06-20
US79236006P 2006-04-14 2006-04-14
PCT/US2006/024182 WO2007002222A2 (en) 2005-06-20 2006-06-20 Psma antibody-drug conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013000244A Division JP6063747B2 (ja) 2005-06-20 2013-01-04 Ｐｓｍａ抗体薬物複合体

Publications (2)

Publication Number Publication Date
JP2008546792A true JP2008546792A (ja) 2008-12-25
JP2008546792A5 JP2008546792A5 (enExample) 2009-08-06

Family

ID=37460276

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008518359A Withdrawn JP2008546792A (ja) 2005-06-20 2006-06-20 Ｐｓｍａ抗体薬物複合体
JP2013000244A Expired - Fee Related JP6063747B2 (ja) 2005-06-20 2013-01-04 Ｐｓｍａ抗体薬物複合体
JP2015095276A Pending JP2015187117A (ja) 2005-06-20 2015-05-07 Ｐｓｍａ抗体薬物複合体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013000244A Expired - Fee Related JP6063747B2 (ja) 2005-06-20 2013-01-04 Ｐｓｍａ抗体薬物複合体
JP2015095276A Pending JP2015187117A (ja) 2005-06-20 2015-05-07 Ｐｓｍａ抗体薬物複合体

Country Status (14)

Country Link
US (2) US20070160617A1 (enExample)
EP (1) EP1912677B1 (enExample)
JP (3) JP2008546792A (enExample)
KR (3) KR20140084242A (enExample)
CN (2) CN103127523A (enExample)
AU (1) AU2006262231B2 (enExample)
BR (1) BRPI0612529A2 (enExample)
CA (1) CA2612762C (enExample)
DK (1) DK1912677T3 (enExample)
ES (1) ES2440482T3 (enExample)
NZ (1) NZ565075A (enExample)
PL (1) PL1912677T3 (enExample)
PT (1) PT1912677E (enExample)
WO (1) WO2007002222A2 (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008541711A (ja) * 2005-05-27 2008-11-27 ユニベルシテーツクリニクム フライブルグ 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント
JP2012519711A (ja) * 2009-03-06 2012-08-30 アジェンシス，インコーポレイテッド ２４ｐ４ｃ１２タンパク質に結合する抗体薬物結合体（ａｄｃ）
JP2013518912A (ja) * 2010-02-08 2013-05-23 アジェンシス，インコーポレイテッド １６１ｐ２ｆ１０ｂタンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）
JP2014516050A (ja) * 2011-05-27 2014-07-07 アンブルックス，インコーポレイテッド 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
US8779111B2 (en) 1999-04-12 2014-07-15 Agensys, Inc. Antibodies to tumor associated proteins
JP2014516987A (ja) * 2011-05-27 2014-07-17 アンブルックス，インコーポレイテッド 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
JP2015521590A (ja) * 2012-06-07 2015-07-30 アンブルックス, インコーポレイテッドAmbrx, Inc. 前立腺特異的膜抗原抗体薬物複合体
JP2016521707A (ja) * 2013-06-04 2016-07-25 シトムクス セラピューティクス，インコーポレイティド 活性化可能抗体を結合するための組成物及び方法
JP2023519261A (ja) * 2020-03-25 2023-05-10 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｐｓｍａ抗体－エキサテカン類似体複合体及びその医薬用途
JP2024503924A (ja) * 2021-01-27 2024-01-29 ヤンセン バイオテツク，インコーポレーテツド カリクレイン関連ペプチダーゼ２抗原結合ドメインを含む免疫コンジュゲート及びその使用

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
EP2360169B1 (en) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
NZ580132A (en) 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins
CN104383553A (zh) 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
US9193763B2 (en) * 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2185188B1 (en) * 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
US8039597B2 (en) * 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
EP2281004A4 (en) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
PT2291659E (pt) 2008-05-13 2016-01-22 Univ Yale Moléculas quiméricas pequenas para o recrutamento de anticorpos contra células cancerosas
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
EP2727606A3 (en) * 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
CN102333544A (zh) 2009-02-06 2012-01-25 通用医疗公司 治疗血管损伤的方法
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2542576B1 (en) * 2010-03-02 2016-04-20 Seattle Genetics, Inc. Methods for screening antibodies
SG194510A1 (en) 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
RU2737765C2 (ru) * 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
AU2013274078A1 (en) * 2012-06-14 2015-01-29 Ambrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
WO2014057114A1 (en) * 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
JP2015536323A (ja) 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 非天然アミノ酸を含む薬物送達結合体および使用方法
AU2013344778C1 (en) 2012-11-15 2024-06-27 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
WO2014088950A1 (en) * 2012-12-07 2014-06-12 3M Innovative Properties Company Method of making transparent conductors on a substrate
EP3964237B1 (en) 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
CA2899577C (en) * 2013-04-03 2023-10-17 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP3019533B1 (en) 2013-07-11 2020-01-08 The Scripps Research Institute Coiled coil immunoglobulin fusion proteins and compositions thereof
WO2015057250A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JP6908964B2 (ja) * 2013-10-18 2021-07-28 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Ｐｓｍａリガンドコンジュゲートによる併用療法
CN105849568B (zh) 2013-11-14 2018-05-04 恩多塞特公司 用于正电子发射断层术的化合物
US20150147339A1 (en) 2013-11-15 2015-05-28 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
JP6636925B2 (ja) 2013-12-17 2020-01-29 ノバルティス アーゲー 細胞障害性ペプチドおよびその抱合体
SG10201913977TA (en) 2014-05-22 2020-03-30 Synthon Biopharmaceuticals Bv Site-specific conjugation of linker drugs to antibodies and resulting adcs
EA201692530A1 (ru) 2014-06-13 2017-07-31 Новартис Аг Цитотоксические пептиды и их конъюгаты
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
SG10201902924RA (en) 2014-10-03 2019-05-30 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
KR20240142591A (ko) 2015-03-27 2024-09-30 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
AU2016282723B2 (en) 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
EP3331573A4 (en) * 2015-08-06 2019-02-27 City of Hope THERAPEUTIC CELL-INTERNALIZING CONJUGATES
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MY198605A (en) 2016-01-25 2023-09-08 Regeneron Pharma Maytansinoid derivatives conjugates thereof, and methods of use
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
US20170296679A1 (en) 2016-04-18 2017-10-19 Intuitive Surgical Operations, Inc. Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands
PE20190622A1 (es) 2016-06-02 2019-04-26 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
KR102556826B1 (ko) 2016-12-21 2023-07-18 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
WO2018178277A1 (en) 2017-03-29 2018-10-04 Avicenna Oncology Gmbh New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof
CA3056261A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
CN110662762A (zh) 2017-05-24 2020-01-07 诺华股份有限公司 抗体细胞因子移植蛋白和用于治疗癌症的方法
CN113952469A (zh) * 2017-06-19 2022-01-21 四川百利药业有限责任公司 一种带酸性自稳定接头的抗体-药物偶联物
MA49796A (fr) 2017-12-01 2020-06-03 Abbvie Inc Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
MX2020009842A (es) * 2018-03-23 2020-10-15 Seattle Genetics Inc Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido.
KR20210003135A (ko) 2018-04-17 2021-01-11 엔도사이트, 인코포레이티드 암의 치료 방법
TW202019487A (zh) 2018-08-06 2020-06-01 日商第一三共股份有限公司 抗體-藥物結合物及微管蛋白抑制劑之組合
FR3085952B1 (fr) 2018-09-17 2020-10-30 Centre Nat Rech Scient Conjugue anticorps-medicament comprenant des derives de quinoline
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
JP7604397B2 (ja) 2019-05-20 2024-12-23 エンドサイト・インコーポレイテッド Ｐｓｍａコンジュゲートの調製方法
DE102019135564B4 (de) * 2019-12-20 2022-05-19 Johannes-Gutenberg-Universität Mainz Verbindung für Smart-Drug-Delivery und pharmazeutisches Kit für duale nuklearmedizinisch-cytotoxische Theranostik
US20250213715A1 (en) * 2020-10-18 2025-07-03 Ardeagen Corporation Anti-cspg4 binding agents, conjugates thereof and methods of using the same
US20230414762A1 (en) * 2020-11-17 2023-12-28 The Johns Hopkins University Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
CA3237590A1 (en) 2021-11-09 2023-05-08 James Basilion Psma targeted conjugate compounds and uses thereof
WO2024027795A1 (zh) * 2022-08-04 2024-02-08 苏州开拓药业股份有限公司 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
CN116196428B (zh) * 2023-04-04 2025-04-04 上海愿智生物技术有限公司 一种药物组合物及其应用
CN121568723A (zh) * 2023-08-04 2026-02-24 江苏恒瑞医药股份有限公司 抗psma抗体-药物偶联物及其医药用途
CN121130102A (zh) * 2024-06-14 2025-12-16 长春金赛药业有限责任公司 靶向b7-h3和psma的双特异性抗体及抗体-药物偶联物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003034903A2 (en) * 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1019163A (en) * 1963-01-23 1966-02-02 Robert Dorfman A collapsible cap or the like
FR2554327A1 (fr) * 1983-11-03 1985-05-10 Gamerdinger Philippe Chapeau monopiece
JPS61137624U (enExample) * 1985-02-15 1986-08-27
JPS6270126U (enExample) * 1985-10-23 1987-05-02
GB8814827D0 (en) * 1988-06-22 1988-07-27 Caple I Planar article
JPH0460516U (enExample) * 1990-09-27 1992-05-25
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH0712435U (ja) * 1993-07-29 1995-02-28 規子 山内 組み立て帽子セット
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US5804602A (en) * 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
FR2818660B1 (fr) * 2000-12-27 2005-03-11 Agronomique Inst Nat Rech Levures transformees par des genes augmentant leur tolerance au stress froid
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20050215472A1 (en) * 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ES2544527T3 (es) * 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
WO2004067564A2 (en) * 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
EP3434275A1 (en) * 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
JP2008519863A (ja) * 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
JP5171621B2 (ja) * 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003034903A2 (en) * 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6011068223; ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ ＶＯＬ．６３, 2003, Ｐ．６３８７-６３９４ *
JPN6011068224; ＢＯＯＫ　ＯＦ　ＡＢＳＴＲＡＣＴＳ．　２２８ＴＨ　ＡＣＳ　ＮＡＴＩＯＮＡＬ　ＭＥＥＴＩＮＧ，　ＡＵＧＵＳＴ　２２-２６，　２００４，　ＰＨＩＬＡＤＥＬＰＨＩＡ，ＰＡ , 2004, ｐ．Ｕ９０８，　１０． *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8779111B2 (en) 1999-04-12 2014-07-15 Agensys, Inc. Antibodies to tumor associated proteins
JP2008541711A (ja) * 2005-05-27 2008-11-27 ユニベルシテーツクリニクム フライブルグ 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント
JP2012519711A (ja) * 2009-03-06 2012-08-30 アジェンシス，インコーポレイテッド ２４ｐ４ｃ１２タンパク質に結合する抗体薬物結合体（ａｄｃ）
US9308278B2 (en) 2010-02-08 2016-04-12 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
JP2013518912A (ja) * 2010-02-08 2013-05-23 アジェンシス，インコーポレイテッド １６１ｐ２ｆ１０ｂタンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）
JP2019131616A (ja) * 2010-02-08 2019-08-08 アジェンシス，インコーポレイテッド １６１ｐ２ｆ１０ｂタンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）
JP2017095459A (ja) * 2010-02-08 2017-06-01 アジェンシス，インコーポレイテッド １６１ｐ２ｆ１０ｂタンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）
US11420999B2 (en) 2011-05-27 2022-08-23 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
JP2018109033A (ja) * 2011-05-27 2018-07-12 アンブルックス, インコーポレイテッドAmbrx, Inc. 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
JP2014516987A (ja) * 2011-05-27 2014-07-17 アンブルックス，インコーポレイテッド 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
JP2014516050A (ja) * 2011-05-27 2014-07-07 アンブルックス，インコーポレイテッド 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
JP2023002671A (ja) * 2011-05-27 2023-01-10 アンブルックス，インコーポレイテッド 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
JP2024170587A (ja) * 2011-05-27 2024-12-10 アンブルックス，インコーポレイテッド 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
JP7638942B2 (ja) 2011-05-27 2025-03-04 アンブルックス，インコーポレイテッド 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
US12622944B2 (en) 2011-05-27 2026-05-12 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
JP2015521590A (ja) * 2012-06-07 2015-07-30 アンブルックス, インコーポレイテッドAmbrx, Inc. 前立腺特異的膜抗原抗体薬物複合体
JP2016521707A (ja) * 2013-06-04 2016-07-25 シトムクス セラピューティクス，インコーポレイティド 活性化可能抗体を結合するための組成物及び方法
JP2023519261A (ja) * 2020-03-25 2023-05-10 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｐｓｍａ抗体－エキサテカン類似体複合体及びその医薬用途
JP2024503924A (ja) * 2021-01-27 2024-01-29 ヤンセン バイオテツク，インコーポレーテツド カリクレイン関連ペプチダーゼ２抗原結合ドメインを含む免疫コンジュゲート及びその使用

Also Published As

Publication number Publication date
AU2006262231A1 (en) 2007-01-04
DK1912677T3 (da) 2014-01-13
EP1912677B1 (en) 2013-10-02
PL1912677T3 (pl) 2014-03-31
EP1912677A2 (en) 2008-04-23
CN101287498B (zh) 2013-03-27
NZ565075A (en) 2011-05-27
WO2007002222A2 (en) 2007-01-04
US20070160617A1 (en) 2007-07-12
CN103127523A (zh) 2013-06-05
KR20140084242A (ko) 2014-07-04
CA2612762A1 (en) 2007-01-04
ES2440482T3 (es) 2014-01-29
BRPI0612529A2 (pt) 2010-11-23
AU2006262231B2 (en) 2013-01-24
CN101287498A (zh) 2008-10-15
US20210023094A1 (en) 2021-01-28
HK1116697A1 (en) 2009-01-02
KR20080031296A (ko) 2008-04-08
JP2013100314A (ja) 2013-05-23
JP2015187117A (ja) 2015-10-29
KR20150126978A (ko) 2015-11-13
WO2007002222A3 (en) 2007-08-09
CA2612762C (en) 2013-12-10
JP6063747B2 (ja) 2017-01-18
PT1912677E (pt) 2013-12-23

Similar Documents

Publication Publication Date Title
JP6063747B2 (ja) Ｐｓｍａ抗体薬物複合体
US9242012B2 (en) Methods for killing PSMA-expressing, taxane-resistant cancer cells
US9695248B2 (en) PSMA antibodies and uses thereof
JP7716836B2 (ja) Ｐｓｍａリガンドコンジュゲートによる併用療法
KR101783529B1 (ko) 항체-약물 접합체
WO2005042029A2 (en) Psma formulations and uses thereof
JP2007500236A (ja) 組換え抗ｃｄ３０抗体とその使用
JP2005523683A (ja) Ｐｓｍａ抗体およびタンパク質マルチマー
JP2008546792A5 (enExample)
JP2025512466A (ja) 抗可変ｍｕｃ１＊抗体およびその使用
HK1186110A (en) Psma antibody-drug conjugates
HK1116697B (en) Psma antibody-drug conjugates
HK1159474B (en) Compounds for killing psma-expressing, taxane- resistant cancer cells
HK1161722A (en) Psma antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120409

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120509

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120605

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130121

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130306

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140415

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140521

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140526

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140918